Residency · Residency · Hematology Thrombosis

Hematopoiesis and Bone Marrow Examination

Introduction and Clinical Context

Hematopoiesis is the tightly regulated process by which all mature blood cells are generated from a small pool of pluripotent hematopoietic stem cells residing in the bone marrow. This process is continuous throughout life, producing approximately 500 billion cells per day in the adult human, and its disruption underlies the majority of hematologic diseases encountered in clinical practice. A thorough understanding of normal hematopoiesis, from the molecular signals governing stem cell self-renewal and lineage commitment to the morphologic milestones of cellular maturation, forms the essential foundation for interpreting bone marrow pathology in both malignant and non-malignant disorders.

The bone marrow examination remains the gold standard for diagnosing and staging many hematologic diseases, including acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphoma staging, plasma cell neoplasms, and a host of non-neoplastic conditions ranging from aplastic anemia to granulomatous infections. The ability to systematically evaluate an aspirate and core biopsy specimen, integrate the findings with flow cytometry, cytogenetics, and molecular data, and synthesize a clinically actionable interpretation is a core competency for the hematology fellow.

Hematopoietic Stem Cell Biology

Stem Cell Hierarchy

At the apex of the hematopoietic hierarchy reside long-term hematopoietic stem cells (LT-HSCs), which are defined by their capacity for self-renewal and their ability to reconstitute the entire blood system when transplanted into a myeloablated host. These cells are largely quiescent, spending the majority of their lifespan in the G0 phase of the cell cycle, and they are immunophenotypically characterized as CD34+/CD38-/CD90+/CD49f+. Their quiescence is maintained by signals from the endosteal niche and is critical for preserving the stem cell pool over decades and preventing the accumulation of DNA replication errors.

Short-term HSCs (ST-HSCs) arise from LT-HSCs and retain multilineage differentiation potential but have a limited capacity for self-renewal, typically sustaining hematopoiesis for weeks to months rather than a lifetime. ST-HSCs give rise to multipotent progenitors (MPPs), which represent the first major branch point in the hematopoietic tree. MPPs subsequently differentiate into common myeloid progenitors (CMPs) and common lymphoid progenitors (CLPs), each committed to producing the mature cells of their respective lineages.

The CMP population bifurcates further into granulocyte-monocyte progenitors (GMPs), which generate neutrophils, monocytes, eosinophils, and basophils, and megakaryocyte-erythroid progenitors (MEPs), which give rise to erythrocytes and platelets through the megakaryocyte pathway. These lineage decisions are governed by complex transcription factor networks. GATA-1 is the master regulator of erythroid and megakaryocytic differentiation, while PU.1 drives myeloid and lymphoid commitment. C/EBPalpha is essential for granulocyte development, and PAX5 is required for B-cell lineage commitment. The balance between these and other transcription factors at each branch point determines the fate of individual progenitor cells.

Bone Marrow Microenvironment (Niche)

Hematopoietic stem cells do not exist in isolation; they depend on a highly specialized microenvironment, termed the stem cell niche, for the signals that regulate their quiescence, self-renewal, differentiation, and mobilization. Two principal niches have been described. The endosteal niche, located at the bone-marrow interface, is composed of osteoblasts and their associated stromal cells. These cells maintain HSC quiescence through Notch signaling, Wnt pathway modulation, and angiopoietin/Tie2 interactions. The perivascular niche surrounds marrow sinusoidal blood vessels and is populated by CXCL12-abundant reticular (CAR) cells, leptin receptor-positive mesenchymal stromal cells, and endothelial cells, all of which provide critical trophic support.

The CXCL12/CXCR4 signaling axis is particularly important for HSC retention within the marrow. CXCL12 (also known as stromal cell-derived factor 1) produced by niche cells binds CXCR4 on HSCs, anchoring them in the marrow space. This axis is therapeutically exploited during stem cell mobilization: granulocyte colony-stimulating factor (G-CSF) disrupts CXCL12/CXCR4 interactions, while plerixafor (AMD3100) is a direct CXCR4 antagonist, and both are used to mobilize HSCs into the peripheral blood for collection and transplantation. An additional layer of regulation comes from the sympathetic nervous system, which modulates HSC egress from the marrow via circadian rhythms mediated by beta-3-adrenergic signaling on niche cells.

Hematopoietic Growth Factors

The production of mature blood cells is governed by a network of hematopoietic growth factors, each of which acts on specific progenitor populations to promote survival, proliferation, and differentiation. Erythropoiesis is primarily driven by erythropoietin (EPO), produced by peritubular fibroblasts of the kidney in response to hypoxia, with contributions from stem cell factor (SCF) and interleukin-3 (IL-3). Granulopoiesis depends on G-CSF, GM-CSF, and IL-3, which promote the expansion and maturation of neutrophil precursors. Megakaryopoiesis and subsequent platelet production are regulated by thrombopoietin (TPO), which is produced primarily in the liver, along with IL-11. Monocyte and macrophage development is supported by M-CSF and GM-CSF. Lymphopoiesis depends on IL-7 for both B-cell and T-cell development, while IL-15 is critical for NK cell maturation. The clinical importance of these growth factors is reflected in the widespread therapeutic use of recombinant EPO, G-CSF, and TPO receptor agonists.

<image>A detailed hierarchical flowchart of hematopoiesis showing the progression from long-term hematopoietic stem cells (LT-HSC) at the top, branching through short-term HSCs, multipotent progenitors, common myeloid progenitors (CMP) and common lymphoid progenitors (CLP), then further branching to granulocyte-monocyte progenitors (GMP) and megakaryocyte-erythroid progenitors (MEP). Each branch should show the key transcription factors (GATA-1, PU.1, C/EBPα, PAX5) at the decision points, and terminate in mature cell types: neutrophils, monocytes, eosinophils, basophils, erythrocytes, platelets, B cells, T cells, and NK cells. Include the key cytokines (EPO, G-CSF, TPO, IL-7) alongside each lineage. Use a clean medical textbook style with color coding for each lineage.</image>

Normal Bone Marrow Anatomy and Cellularity

Age-Related Cellularity

Bone marrow cellularity, defined as the percentage of marrow space occupied by hematopoietic tissue relative to fat, changes predictably with age. In neonates, the marrow is nearly 100% cellular, reflecting the intense hematopoietic demands of early life. By young adulthood (ages 20 to 30), cellularity decreases to approximately 60 to 70 percent, and it continues to decline gradually thereafter. A commonly used rule of thumb estimates cellularity as approximately 100 minus the patient's age, with a margin of plus or minus 10 percent, though this is an approximation and considerable individual variation exists. It is essential to note that cellularity must be assessed on the core biopsy specimen rather than the aspirate, and that subcortical areas of the biopsy may be artifactually hypocellular, making it important to evaluate cellularity in the deeper portions of the biopsy core.

Normal Myeloid:Erythroid (M:E) Ratio

The myeloid-to-erythroid (M:E) ratio provides a quantitative assessment of the relative proportions of granulocytic and erythroid precursors in the marrow. The normal M:E ratio ranges from 2:1 to 4:1, reflecting the typically greater abundance of myeloid precursors. An elevated M:E ratio may be seen in the setting of infection (reactive granulocytic hyperplasia), chronic myeloid leukemia, other myeloid neoplasms, or erythroid hypoplasia such as pure red cell aplasia. A decreased M:E ratio suggests erythroid hyperplasia, as occurs in hemolytic anemias and megaloblastic anemias, or alternatively may reflect myeloid suppression.

Normal Maturation Sequences

The erythroid maturation sequence progresses from the pronormoblast, the earliest recognizable erythroid precursor, through basophilic, polychromatic, and orthochromatic normoblast stages, followed by extrusion of the nucleus to form the reticulocyte, which matures in the peripheral blood over approximately one to two days into the mature red blood cell. The entire transit time from pronormoblast to circulating reticulocyte is approximately five days.

Myeloid maturation begins with the myeloblast and proceeds through the promyelocyte (characterized by the appearance of primary azurophilic granules), the myelocyte (where secondary or specific granules appear and cell division ceases), the metamyelocyte, the band neutrophil, and finally the segmented mature neutrophil. The total transit time through the marrow is approximately 10 to 14 days.

Megakaryocyte maturation involves a unique process of endomitosis, in which DNA replication occurs without cell division, resulting in large polyploid cells with a ploidy typically ranging from 8N to 64N. The megakaryoblast matures through the promegakaryocyte stage to the mature megakaryocyte, which extends long cytoplasmic processes called proplatelets into sinusoidal blood vessels, where shear forces fragment them into individual platelets. A single mature megakaryocyte produces approximately 2,000 to 3,000 platelets.

Bone Marrow Examination Technique

Indications

Bone marrow examination is indicated in a wide range of clinical scenarios. The most common indications include the evaluation of unexplained cytopenias (anemia, leukopenia, or thrombocytopenia) or cytoses (leukocytosis, erythrocytosis, or thrombocytosis) that cannot be adequately explained by peripheral blood findings alone. Staging of hematologic malignancies, including lymphoma, myeloma, myelodysplastic syndromes, and acute leukemia, frequently requires marrow assessment. The bone marrow iron stain remains a definitive method for assessing body iron stores when non-invasive tests are ambiguous. Additional indications include the evaluation of fever of unknown origin, where granulomatous disease or hemophagocytic syndromes may be identified; the diagnosis of storage diseases and infiltrative processes such as metastatic carcinoma; and the assessment of engraftment following hematopoietic stem cell transplantation.

Procedure

The preferred site for bone marrow biopsy is the posterior superior iliac spine (PSIS), which provides safe access to a generous marrow space with minimal risk of injury to underlying structures. Alternative sites include the anterior iliac crest and, for aspirate only, the sternum, though sternal aspiration carries a higher risk of penetration into the mediastinum and is generally reserved for situations where the iliac crest is not accessible.

Local anesthesia is achieved with 1% lidocaine, applied first to the skin and subcutaneous tissue and then, critically, to the periosteum. Adequate periosteal anesthesia is the single most important factor for procedural pain control. The aspirate is collected first, with an initial pull of 0.5 to 1 mL; larger volumes increase hemodilution with peripheral blood and degrade specimen quality. The core biopsy is obtained using a trephine needle, most commonly a Jamshidi-type device, and a minimum core length of 1.5 cm is recommended by current guidelines, with an ideal length of 2 cm or more to ensure adequate assessment of cellularity and architecture. Touch preparations, or imprint slides, are made from the core biopsy to provide cytologic detail that complements the histologic sections.

Specimen Processing

Aspirate smears are stained with Wright-Giemsa stain and examined under light microscopy. A 500-cell differential count is performed to quantify the proportions of each cell type and to identify any morphologic abnormalities. The core biopsy undergoes decalcification to remove mineral content, followed by embedding, sectioning, and staining with hematoxylin and eosin (H&E) for general morphology and reticulin stain (silver impregnation) for assessment of marrow fibrosis.

Flow cytometry is performed on aspirate material to provide rapid immunophenotypic characterization of cell populations. A minimum of 200,000 events is typically analyzed, and standardized antibody panels are used for lineage assignment, blast characterization, and detection of minimal residual disease or paroxysmal nocturnal hemoglobinuria clones. Cytogenetic studies include conventional karyotyping, which requires viable dividing cells and analyzes a standard 20 metaphase spreads, and fluorescence in situ hybridization (FISH), which uses targeted probes to detect specific translocations, deletions, or amplifications. Molecular studies, including PCR and next-generation sequencing (NGS) panels covering 30 to 50 genes, are increasingly standard in the workup of MDS, AML, CMML, and MPNs, and provide critical information for risk stratification and therapeutic decision-making.

<image>An annotated cross-sectional diagram of a bone marrow core biopsy procedure at the posterior superior iliac spine. Show the layers from skin through subcutaneous tissue, cortical bone, and into the medullary cavity. Include the trephine biopsy needle positioned through cortical bone into the marrow space. Label the aspirate needle and core biopsy needle separately. Inset panels should show: (1) a representative aspirate smear with identifiable erythroid and myeloid precursors, (2) a core biopsy section showing normal trilineage hematopoiesis with fat spaces, and (3) a touch preparation. Medical illustration style with anatomical accuracy.</image>

Systematic Bone Marrow Interpretation

Aspirate Assessment (10-Step Approach)

A systematic approach to aspirate interpretation ensures that critical findings are not overlooked. The following 10-step framework provides a comprehensive evaluation.

First, the overall cellularity is estimated from the aspirate particle sections, though this must be confirmed on the core biopsy, which provides a more reliable assessment. Second, megakaryocytes are evaluated for their number, morphology, and any tendency toward clustering, which may suggest a myeloproliferative neoplasm. Third, the erythroid series is examined for orderly maturation and for evidence of dysplasia, including nuclear budding, multinucleation, and megaloblastoid change. Fourth, the myeloid series is assessed for maturation, left shift (an increase in immature forms), and dysplasia, notably hypolobation of neutrophil nuclei (pseudo-Pelger-Huet anomaly) and hypogranularity.

Fifth, the blast count is determined. By WHO criteria, a blast percentage of 20% or greater in the marrow defines acute leukemia. Myeloblasts are counted on a 500-cell differential. Sixth, the proportions of lymphocytes and plasma cells are quantified; normal values are less than 10% lymphocytes and less than 3% plasma cells. Seventh, the counts of monocytes, eosinophils, and basophils are assessed for any significant increase. Eighth, the iron stain (Prussian blue) is evaluated for storage iron, which is graded from 0 (absent) to 6 (massive) based on macrophage hemosiderin content, and for ring sideroblasts, defined as erythroblasts with five or more iron granules encircling at least one-third of the nucleus. Ninth, the examiner looks for special findings such as granulomas, hemophagocytosis, parasites, or metastatic tumor cells. Tenth, artifacts are noted, including hemodilution and crush artifact, which may compromise specimen quality.

Core Biopsy Assessment

The core biopsy provides architectural information that cannot be obtained from the aspirate alone. Cellularity is assessed as the percentage of marrow space occupied by hematopoietic tissue relative to adipose tissue. The architectural pattern of any infiltrate is characterized as interstitial (diffusely scattered cells), paratrabecular (cells lining bone trabeculae, characteristic of follicular lymphoma), nodular (discrete aggregates), diffuse, or packed.

Fibrosis grading follows a standardized scale. MF-0 indicates scattered linear reticulin fibers with no intersections, representing normal marrow. MF-1 denotes a loose network of reticulin with many intersections, indicating early fibrosis. MF-2 is defined by diffuse, dense reticulin with focal collagen bundles. MF-3 represents the most severe grade, with coarse collagen bundles and osteosclerosis.

Ancillary Studies

Flow cytometry is essential for blast characterization, providing the immunophenotypic profile needed for lineage assignment in acute leukemias and for the detection of aberrant antigen expression used in minimal residual disease monitoring. It is also the test of choice for identifying PNH clones through FLAER and CD59 analysis. Cytogenetic analysis with 20 metaphase examination is the standard, and specific cytogenetic abnormalities define distinct WHO disease entities. FISH is used when karyotyping fails to yield adequate metaphases or when targeted detection of specific abnormalities is needed. Next-generation sequencing myeloid panels, typically covering 30 to 50 genes, are increasingly integrated into the initial diagnostic workup and are essential for molecular risk stratification.

<image>A side-by-side comparison panel showing four bone marrow core biopsy photomicrographs demonstrating the reticulin fibrosis grading scale (MF-0 through MF-3). MF-0 should show scattered thin reticulin fibers with no intersections against a background of normal cellularity. MF-1 should show a loose network of reticulin with intersections. MF-2 should show dense reticulin with focal collagen bundles (trichrome-positive areas). MF-3 should show coarse collagen bundles with osteosclerosis. Each panel should be clearly labeled with the grade and a brief descriptor. Include both reticulin (silver) stain and trichrome stain views. Medical pathology style.</image>

Common Bone Marrow Patterns in Disease

Hypercellular Marrow

A hypercellular marrow may be reactive or neoplastic. Reactive causes include infection, recovery from chemotherapy (regenerating marrow), and growth factor administration, all of which stimulate hematopoietic expansion in a physiologically appropriate manner. Neoplastic causes encompass the myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis), myelodysplastic syndromes (which are paradoxically hypercellular in most cases despite peripheral cytopenias), acute leukemias, and chronic myeloid leukemia. Distinguishing reactive from neoplastic hypercellularity requires integration of morphologic findings with flow cytometry, cytogenetics, and molecular data.

Hypocellular Marrow

Hypocellularity is defined relative to age-adjusted norms. The most important cause is aplastic anemia, in which cellularity is often below 25% in severe disease. Hypoplastic MDS accounts for 10 to 15% of MDS cases and can closely mimic aplastic anemia, making distinction challenging. Key features that favor MDS over aplastic anemia include the presence of dysplasia in at least 10% of one or more lineages, increased blasts, abnormal cytogenetics such as monosomy 7, and specific somatic mutations. Post-chemotherapy and post-radiation marrow may also be hypocellular, typically in a predictable temporal pattern related to the treatment administered.

Granulomatous Marrow

Granulomas in the bone marrow may have infectious or non-infectious etiologies. Infectious causes include mycobacterial infections (both tuberculous and non-tuberculous), fungal infections (particularly Histoplasma capsulatum and Coccidioides species), Brucella, and Q fever. Non-infectious causes include sarcoidosis, drug reactions, and foreign body responses. When granulomas are identified, cultures and special stains for acid-fast bacilli (AFB) and fungi (GMS, Grocott methenamine silver) should always be sent, as the morphologic appearance alone cannot reliably distinguish infectious from non-infectious granulomas.

Hemophagocytic Pattern

The hemophagocytic pattern is characterized by activated macrophages that are morphologically identified engulfing erythrocytes, leukocytes, and platelets. This finding is supportive of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS), conditions characterized by markedly elevated serum ferritin (often exceeding 10,000 ng/mL), elevated soluble IL-2 receptor (sIL-2R), hypertriglyceridemia, and low fibrinogen. However, hemophagocytosis in the bone marrow, while supportive, is not pathognomonic for HLH; its specificity is approximately 80%, and it can be seen in other conditions including severe infections, autoimmune diseases, and following transfusion. Clinical correlation with the full HLH diagnostic criteria is essential.

Key Clinical Pearls

• Always correlate the aspirate with the core biopsy; a "dry tap" (aspicular aspirate) may indicate fibrosis, packed marrow, or technical failure - the core biopsy is essential
• A minimum core biopsy length of 1.5-2.0 cm is critical for accurate cellularity and architectural assessment
• Ring sideroblasts on iron stain have specific diagnostic implications: ≥15% ring sideroblasts or ≥5% with SF3B1 mutation defines MDS-RS (WHO 2022)
• Flow cytometry blast gates (CD45 dim/low SSC) are more accurate than morphologic blast counts in many settings
• Hemodiluted aspirates are a common pitfall; always compare cellularity on aspirate vs. biopsy and look at particle sections
• When interpreting M:E ratio, remember that a "left-shifted" myeloid series with increased promyelocytes/myelocytes is distinct from increased blasts

References

1. Swerdlow SH, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th Edition. IARC Press, 2017.
2. Khoury JD, et al. The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours. Leukemia. 2022;36(7):1703-1719.
3. Bain BJ. Bone marrow aspiration. J Clin Pathol. 2001;54(9):657-663.
4. Lee SH, et al. Bone marrow trephine biopsy: guideline from the British Committee for Standards in Haematology. Br J Haematol. 2008;142(2):227-233.
5. Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014;505(7483):327-334.

Read this lecture as Markdown